My Healing CommunityIntegrative Oncology Field Guide
Natural medicinesMelatonin in Oncology - Study Notes

Addendum — Dosing, Th1/Th2, and Recalibration

Why continuous high-dose oral melatonin may undermine the immune-support goal, and how to think about recalibrating use

This addendum restores the full practical distinction from the source notes.

A transient high-exposure ROS pulse is not the same thing as continuous oral mega-dosing.

What the Th1/Th2 dose-dependent finding actually says

The main concern is not simple toxicity.

It is that chronic high melatonin exposure may blunt Th1 signalling.

That means lower IFN-γ and IL-12-linked priming at the point where anti-tumour immunity needs them most.

The key study here is Szczepanik et al. 2007.

In a Th1-dependent immune model, melatonin suppressed IFN-γ and IL-12 production in lymph node cells.

The broader point is dose-dependent.

Lower exposure can support Th1 activity.

Higher exposure can shift toward Th2 or broader immunosuppressive signalling.

That pattern is consistent with later review and dendritic-cell literature as well.

  • Carrillo-Vico et al. describe melatonin as a dose-sensitive, double-edged inflammatory regulator.

  • Huang et al. 2024 show melatonin can suppress Th1 and Th17 responses through dendritic-cell NF-κB inhibition.

Where this matters most in the cancer-immunity cycle

The strongest leverage point is Step 3 of the cancer-immunity cycle.

That is the priming and activation phase in the lymph nodes.

This is where dendritic cells present tumour antigens and need Th1-skewed help to set up the rest of the response.

That includes:

  • efficient CD8 cross-priming

  • stronger memory formation

  • more tumouricidal macrophage polarisation

If Th1 tone is weak here, later steps can stall.

That includes trafficking, infiltration, recognition, and tumour killing.

So if continuous high-dose melatonin chronically blunts IFN-γ and IL-12 at this step, it can weaken the priming phase before later therapies even get a fair chance to work.

Why the RET mechanism does not justify continuous oral mega-dosing

This is the main practical misunderstanding.

The two key mechanistic studies do not model indefinite oral human use.

  • Benaiges et al. used 40 mg/kg intraperitoneal melatonin in mice

  • Florido et al. used direct 0.5 to 1 mM exposure in cancer cells over a short time window

Both support a brief ROS event.

The cell-line work points to a burst that peaks within roughly 1 to 3 hours.

That burst does not imply that repeating a large oral dose every day creates a stronger and stronger RET effect.

Tumour cells do not appear to experience an endlessly compounding RET stimulus from chronic oral intake.

What rises more reliably with continuous daily use is the ongoing melatonin load.

That shifts the question away from a short pro-oxidant pulse and toward chronic signalling, immune modulation, CYP1A2 effects, and endocrine load.

A supervised short-term high-exposure pulse and unsupervised chronic oral mega-dosing should not be treated as equivalent strategies.

The evidence-supported adjunct window

The clinical and preclinical literature is most consistent in the moderate adjunct range.

For most readers not pursuing a defined supervised pulse strategy, the main evidence-supported range remains:

  • 1 to 20 mg nightly as the lower physiological to low-pharmacological range

  • 20 to 40 mg nightly as the main moderate adjunct range used in human oncology discussions

The main human oral dosing data here comes from the Lissoni trials and the Mills meta-analysis.

Those reports used 20 to 40 mg oral melatonin in cancer patients and measured clinical outcomes, not just laboratory markers.

That is the zone most aligned with:

  • circadian support

  • Th1-skewed immune support

  • IL-2 and IFN-γ support

  • checkpoint-related adjunct logic

By contrast, continuous daily hundreds-of-mg oral use sits in a weaker evidence zone and carries more risk of working against the immune goal.

Route, bioavailability, and the uncertain middle zone

Not all dose claims in the melatonin discussion come from the same type of study.

That matters because route changes exposure.

The Th1-support and clinical-outcome claims come from real human oral trials.

Cancer patients in the Lissoni work took 20 to 40 mg by mouth at night.

Those are swallowed oral doses in actual patients.

No route conversion is needed there.

The RET and some mitochondrial claims come from mice given injections or from cells exposed directly in culture.

That is a different exposure model.

When melatonin is injected intraperitoneally in mice, most of the dose reaches systemic circulation much more directly than a swallowed powder dose in humans.

Using standard scaling, the 40 mg/kg mouse intraperitoneal dose maps to roughly 225 mg reaching the bloodstream in a human-sized adult.

That does not mean swallowing 225 mg plain powder reproduces the model.

With rough oral absorption assumptions:

  • around 2 to 2.3 g plain powder may be needed to deliver about 225 mg systemically

  • around 600 mg swallowed in a high-efficiency liposomal or alcohol-solubilised form may reach a similar systemic exposure

That creates an important middle zone.

A practical example is 400 mg plain powder orally.

That may deliver only about 40 mg systemically.

So it may be:

  • too low to clearly reproduce the mouse-equivalent RET exposure

  • too high to still look like classic human adjunct dosing

That is the uncertain middle zone.

The immune downside may rise before the RET-style upside is even reached.

Recalibration framework

If someone has been taking continuous high doses, the most practical next step is not panic.

It is reassessment.

These effects are pharmacological.

They are not best understood as a permanently fixed immune fate.

Useful next steps include:

  • review the reason for the current dose

  • separate RET-pulse logic from nightly adjunct logic

  • revisit timing, formulation, and interaction questions

  • discuss the protocol with the oncology team when immunotherapy or multiple medicines are involved

If there was no defined supervised RET-pulse rationale, the better-supported default is usually to step back toward the 10 to 40 mg nightly evening range.

That is the range with the clearest human adjunct signal for circadian support, Th1 support, and checkpoint-relevant immune framing.

Bottom line

The better-supported human melatonin use case remains moderate evening adjunct dosing.

Continuous daily high-dose oral use is a different strategy.

It has weaker evidence, greater route uncertainty, and more risk of working against the immune goal.

Related pages

Key references

Fibrotic Drivers and the 26-Gene Signature

Previous Page

Melatonin, Palbociclib, and Cyclin D1

Next Page

On this page

What the Th1/Th2 dose-dependent finding actually saysWhere this matters most in the cancer-immunity cycleWhy the RET mechanism does not justify continuous oral mega-dosingThe evidence-supported adjunct windowRoute, bioavailability, and the uncertain middle zoneRecalibration frameworkBottom lineRelated pagesKey references